Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study.
Inflamm Bowel Dis
; 25(1): 172-179, 2019 01 01.
Article
in En
| MEDLINE
| ID: mdl-29947795
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gastrointestinal Agents
/
Inflammatory Bowel Diseases
/
Biosimilar Pharmaceuticals
/
Infliximab
/
Antibodies, Monoclonal
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Inflamm Bowel Dis
Journal subject:
GASTROENTEROLOGIA
Year:
2019
Document type:
Article
Affiliation country:
Netherlands
Country of publication:
United kingdom